Compare CFFN & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CFFN | ESPR |
|---|---|---|
| Founded | 1893 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 981.1M | 816.9M |
| IPO Year | 2010 | 2013 |
| Metric | CFFN | ESPR |
|---|---|---|
| Price | $8.62 | $3.16 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $7.25 | ★ $8.75 |
| AVG Volume (30 Days) | 792.6K | ★ 9.9M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.51% | N/A |
| EPS Growth | ★ 79.31 | 60.71 |
| EPS | ★ 0.32 | N/A |
| Revenue | $16,300,000.00 | ★ $403,135,000.00 |
| Revenue This Year | $20.16 | N/A |
| Revenue Next Year | $6.62 | $12.81 |
| P/E Ratio | $26.59 | ★ N/A |
| Revenue Growth | 6.54 | ★ 21.31 |
| 52 Week Low | $5.71 | $1.10 |
| 52 Week High | $8.58 | $4.18 |
| Indicator | CFFN | ESPR |
|---|---|---|
| Relative Strength Index (RSI) | 71.05 | 63.17 |
| Support Level | $7.49 | $3.13 |
| Resistance Level | N/A | $3.18 |
| Average True Range (ATR) | 0.16 | 0.02 |
| MACD | 0.03 | -0.02 |
| Stochastic Oscillator | 94.03 | 62.50 |
Capitol Federal Financial Inc is a bank holding company that operates through its wholly-owned subsidiary bank. The bank is a community-oriented financial institution that offers a variety of financial services through tens of locations. It mainly serves metropolitan areas within the state of Kansas. The bank performs traditional banking functions such as deposit-taking activities and investing that money in first-lien residential mortgages. It also participates in commercial real estate loans with other lenders, investing those funds in various securities. The vast majority of the bank's loan portfolio is in originated one- to four-family real estate loans. Its primary source of income is net interest income.
Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.